Liu TQ - Search Results

1

Hexosaminidase B-driven cancer cell-macrophage co-dependency promotes glycolysis addiction and tumorigenesis in glioblastoma.

Zhu C, Chen X, Liu TQ, Cheng L, Cheng W, Cheng P, Wu AH. Zhu C, et al. Among authors: liu tq. Nat Commun. 2024 Oct 1;15(1):8506. doi: 10.1038/s41467-024-52888-0. Nat Commun. 2024. PMID: 39353936 Free PMC article.

2

Dual role of ARPC1B in regulating the network between tumor-associated macrophages and tumor cells in glioblastoma.

Liu T, Zhu C, Chen X, Wu J, Guan G, Zou C, Shen S, Chen L, Cheng P, Cheng W, Wu A. Liu T, et al. Oncoimmunology. 2022 Jan 27;11(1):2031499. doi: 10.1080/2162402X.2022.2031499. eCollection 2022. Oncoimmunology. 2022. PMID: 35111386 Free PMC article.

3

Chemerin enhances mesenchymal features of glioblastoma by establishing autocrine and paracrine networks in a CMKLR1-dependent manner.

Wu J, Shen S, Liu T, Ren X, Zhu C, Liang Q, Cui X, Chen L, Cheng P, Cheng W, Wu A. Wu J, et al. Oncogene. 2022 May;41(21):3024-3036. doi: 10.1038/s41388-022-02295-w. Epub 2022 Apr 22. Oncogene. 2022. PMID: 35459783 Free PMC article.

4

Inhibiting interferon-γ induced cancer intrinsic TNFRSF14 elevation restrains the malignant progression of glioblastoma.

Han Y, Zou C, Liu T, Cheng W, Cheng P, Wu A. Han Y, et al. J Exp Clin Cancer Res. 2024 Jul 31;43(1):212. doi: 10.1186/s13046-024-03131-7. J Exp Clin Cancer Res. 2024. PMID: 39085878 Free PMC article.

5

Costimulatory checkpoint SLAMF8 is an independent prognosis factor in glioma.

Zou CY, Guan GF, Zhu C, Liu TQ, Guo Q, Cheng W, Wu AH. Zou CY, et al. Among authors: liu tq. CNS Neurosci Ther. 2019 Mar;25(3):333-342. doi: 10.1111/cns.13041. Epub 2018 Aug 13. CNS Neurosci Ther. 2019. PMID: 30105842 Free PMC article.

6

Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance.

Liu T, Zhu C, Chen X, Guan G, Zou C, Shen S, Wu J, Wang Y, Lin Z, Chen L, Cheng P, Cheng W, Wu A. Liu T, et al. Neuro Oncol. 2022 Jul 1;24(7):1113-1125. doi: 10.1093/neuonc/noac033. Neuro Oncol. 2022. PMID: 35148413 Free PMC article.

7

Molecular profiling identifies distinct subtypes across TP53 mutant tumors.

Chen X, Liu T, Wu J, Zhu C, Guan G, Zou C, Guo Q, Ren X, Li C, Cheng P, Cheng W, Wu A. Chen X, et al. JCI Insight. 2022 Dec 8;7(23):e156485. doi: 10.1172/jci.insight.156485. JCI Insight. 2022. PMID: 36256461 Free PMC article.

8

Tumor microenvironment remodeling plus immunotherapy could be used in mesenchymal-like tumor with high tumor residual and drug resistant rate.

Shen S, Liu X, Guo Q, Liang Q, Wu J, Guan G, Zou C, Zhu C, Yan Z, Liu T, Chen L, Cheng P, Cheng W, Wu A. Shen S, et al. Commun Biol. 2023 Dec 18;6(1):1281. doi: 10.1038/s42003-023-05667-4. Commun Biol. 2023. PMID: 38110614 Free PMC article.

9

The biological behavior and clinical outcome of pituitary adenoma are affected by the microenvironment.

Li Y, Ren X, Gao W, Cai R, Wu J, Liu T, Chen X, Jiang D, Chen C, Cheng Q, Wu A, Cheng W. Li Y, et al. CNS Neurosci Ther. 2024 May;30(5):e14729. doi: 10.1111/cns.14729. CNS Neurosci Ther. 2024. PMID: 38738958 Free PMC article. Review.

10

Development and validation of an interferon signature predicting prognosis and treatment response for glioblastoma.

Zhu C, Zou C, Guan G, Guo Q, Yan Z, Liu T, Shen S, Xu X, Chen C, Lin Z, Cheng W, Wu A. Zhu C, et al. Oncoimmunology. 2019 Jun 12;8(9):e1621677. doi: 10.1080/2162402X.2019.1621677. eCollection 2019. Oncoimmunology. 2019. PMID: 31428519 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

119 results

Search Page

Filters